Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is... see more

CSE:RVV - Post Discussion

Revive Therapeutics Ltd > Poor trial design, terrible sites, pitiful management
View:
Post by 1ottrunner on Jul 15, 2021 1:34pm

Poor trial design, terrible sites, pitiful management

Which is obvious from todays update.  The trial hasn't even reach 600 patients yet!
Comment by RandomGuy1 on Jul 15, 2021 1:35pm
Please stop.  
Comment by 1ottrunner on Jul 15, 2021 1:36pm
Stop what?  Offering the truth? Trial completion will be updated to end of Q4 at the earliest.
Comment by RandomGuy1 on Jul 15, 2021 1:42pm
Just trolling a bit.  But what's your honest opinion on this?  Is this considered good news for us hoping or is it lacklustre?  Does this imply that they have been performing the trials and thus far, no serious side effects have occurred?  How do you interpret this? To date, the ongoing Study has not seen any serious adverse events or safety concerns that required the ...more  
Comment by 1ottrunner on Jul 15, 2021 1:48pm
The best news is that they have decided on a dose. That means the DSMB reviewed initial data and made that decision. Good news is they could have reviewed it and decided not to continue.  It must mean that the higher dose has efficacy beyond the placebo and lower dose. What we need as investors is real recruitment!  With 40 sites this trial should be fully rectruited in 30 days. M ...more  
Comment by Towser7 on Jul 15, 2021 8:55pm
Fantastic summary.   I really want to know why the recruitment is such an issue.  There's been no comment on that fro MF.  Can't they provide incentives?  The cost would be minimal compared to the potential revenue they will miss out on by continued slow progress.
Comment by captainbrouwer on Jul 16, 2021 1:04am
For a good discussion about trial/update/dosage etc see the live chat on rvvtf subreddit, especially between biomedicaltrader, dalesreport and nostatistician. Ignore 1ottrunner, he's an idiot
Comment by 1ottrunner on Jul 16, 2021 5:40am
Yes the reddit gang, I'm sure they are all very intelligent.  This trial has been running 2 weeks short of a year. You heard it here, 50 weeks.  The trial design has finally enrolled 50% participation. None of the trial sites offer any information regarding this trial, they list others, but not this. So captainbrouwer, how great is this trial designed? You want to know a good ...more  
Comment by captainbrouwer on Jul 16, 2021 6:49am
As usual you don't know what you're talking about dummy
Comment by 90guppy on Jul 16, 2021 9:55am
yep, as usual paid hacks, get paid to bash, must be miserable to do what paid hacks do, aint got dough to make any bet, but bash for pennies
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities